Massachusetts Society of Clinical Oncologists - FDA Approves crizanlizumab-tmca (Adakveo) for Sickle Cell Disease

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA Approves crizanlizumab-tmca (Adakveo) for Sickle Cell Disease

FDA Approves crizanlizumab-tmca (Adakveo) for Sickle Cell Disease

18 Nov 2019 8:54 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved crizanlizumab-tmca (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org